Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 542 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model.
Zelek WM, Bevan RJ, Nimmo J, Dewilde M, De Strooper B, Morgan BP
Brain, awae278, 31 Aug 2024
Cited by: 0 articles | PMID: 39215579
Add to export list
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor.
Sukhun R, Cremin P, Xu D, Zamora J, Cheung J, Ashcraft L, Grillo MP, Morgan BP
Xenobiotica, 54(9):686-700, 09 Aug 2024
Cited by: 0 articles | PMID: 39102472
Add to export list
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [<sup>14</sup>C]aficamten following single oral dose administration to rats.
Grillo MP, Sukhun R, Bashir M, Ashcraft L, Morgan BP
Xenobiotica, 54(9):670-685, 07 Aug 2024
Cited by: 1 article | PMID: 39058619
Add to export list
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.
Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI
Nat Cardiovasc Res, 3(8):1003-1016, 23 Jul 2024
Cited by: 0 articles | PMID: 39196032 | PMCID: PMC11358156
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility.
Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, Chuang C, Hartman J, Hwee DT, St Jean D, Malinowski J, DeBenedetto M, Moebius D, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP
J Med Chem, 67(10):7825-7835, 10 May 2024
Cited by: 1 article | PMID: 38729623 | PMCID: PMC11129190
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy.
Rivas VN, Crofton AE, Jauregui CE, Wouters JR, Yang BS, Wittenburg LA, Kaplan JL, Hwee DT, Murphy AN, Morgan BP, Malik FI, Harris SP, Stern JA
Sci Rep, 14(1):12038, 27 May 2024
Cited by: 0 articles | PMID: 38802475 | PMCID: PMC11130313
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia.
Zelek WM, Bevan RJ, Morgan BP
Brain Behav Immun, 118:355-363, 12 Mar 2024
Cited by: 0 articles | PMID: 38485063
Add to export list
The complement system in neurodegenerative diseases.
Nimmo J, Byrne RAJ, Daskoulidou N, Watkins LM, Carpanini SM, Zelek WM, Morgan BP
Clin Sci (Lond), 138(6):387-412, 01 Mar 2024
Cited by: 0 articles | PMID: 38505993 | PMCID: PMC10958133
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats.
Collibee SE, Romero A, Muci AR, Hwee DT, Chuang C, Hartman JJ, Motani AS, Ashcraft L, DeRosier A, Grillo M, Lu Q, Malik FI, Morgan BP
J Med Chem, 67(10):7859-7869, 07 Mar 2024
Cited by: 2 articles | PMID: 38451215 | PMCID: PMC11129196
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID.
Baillie K, Davies HE, Keat SBK, Ladell K, Miners KL, Jones SA, Mellou E, Toonen EJM, Price DA, Morgan BP, Zelek WM
Med, 5(3):239-253.e5, 15 Feb 2024
Cited by: 7 articles | PMID: 38359836
Add to export list
Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model.
Kamegai N, Kim H, Suzuki Y, Fukui S, Kojima H, Maruyama S, Morgan BP, Zelek WM, Mizuno M
Clin Exp Immunol, 214(2):209-218, 01 Dec 2023
Cited by: 1 article | PMID: 37549240
Add to export list
Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
Bowen EE, Hurcombe JA, Barrington F, Keir LS, Farmer LK, Wherlock MD, Ortiz-Sandoval CG, Bruno V, Bohorquez-Hernandez A, Diatlov D, Rostam-Shirazi N, Wells S, Stewart M, Teboul L, Lay AC, Butler MJ, Pope RJP, Larkai EMS, Morgan BP, [...] Coward RJM
Med, 4(11):761-777.e8, 19 Oct 2023
Cited by: 1 article | PMID: 37863058
Add to export list
Complement-membrane regulatory proteins are absent from the nodes of Ranvier in the peripheral nervous system.
Karbian N, Eshed-Eisenbach Y, Zeibak M, Tabib A, Sukhanov N, Vainshtein A, Morgan BP, Fellig Y, Peles E, Mevorach D
J Neuroinflammation, 20(1):245, 24 Oct 2023
Cited by: 1 article | PMID: 37875972 | PMCID: PMC10594684
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Complement dysregulation is a predictive and therapeutically amenable feature of long COVID
Baillie K, Davies HE, Keat SBK, Ladell K, Miners KL, Jones SA, Mellou E, Toonen EJM, Price DA, Morgan BP, Zelek WM
medRxiv, 28 Oct 2023
Cited by: 0 articles | PPR: PPR749736
Add to export list Preprint Free full text in Europe PMC
Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.
Veteleanu A, Stevenson-Hoare J, Keat S, Daskoulidou N, Zetterberg H, Heslegrave A, Escott-Price V, Williams J, Sims R, Zelek WM, Carpanini SM, Morgan BP
J Neuroinflammation, 20(1):169, 21 Jul 2023
Cited by: 2 articles | PMID: 37480051 | PMCID: PMC10362776
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity.
Goff LM, Davies K, Zelek WM, Kodosaki E, Hakim O, Lockhart S, O'Rahilly S, Morgan BP
Clin Exp Immunol, 212(1):52-60, 01 Apr 2023
Cited by: 0 articles | PMID: 36722378 | PMCID: PMC10081104
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies.
Chen DW, Kang T, Xu XZ, Xia WJ, Ye X, Wu YB, Xu YR, Liu J, Ren H, Deng J, Chen YK, Ding HQ, Aslam M, Zelek WM, Morgan BP, Kapur R, Santoso S, Fu YS
JCI Insight, 8(6):e165142, 22 Mar 2023
Cited by: 1 article | PMID: 36809299 | PMCID: PMC10070104
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis.
Evans R, Watkins LM, Hawkins K, Santiago G, Demetriou C, Naughton M, Dittmer M, Rees MI, Fitzgerald D, Morgan BP, Neal JW, Howell OW
Front Cell Neurosci, 17:1094106, 22 Mar 2023
Cited by: 4 articles | PMID: 37032838 | PMCID: PMC10073739
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Complement receptor 1 is expressed on brain cells and in the human brain.
Daskoulidou N, Shaw B, Torvell M, Watkins L, Cope EL, Carpanini SM, Allen ND, Morgan BP
Glia, 71(6):1522-1535, 24 Feb 2023
Cited by: 10 articles | PMID: 36825534 | PMCID: PMC10953339
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Membrane-bound complement regulator expression in peripheral nerves
Karbian N, Eshed-Eisenbach Y, Zeibak M, Tabib A, Sukhanov N, Vainshtein A, Morgan BP, Fellig Y, Peles E, Mevorach D
Research Square, 28 Mar 2023
Cited by: 0 articles | PPR: PPR637345
Add to export list Preprint v1
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, Marshall R, Sims R, Morgan BP, Hardy J, de Strooper B, Williams J, Zetterberg H, Escott-Price V
Brain, 146(2):690-699, 01 Feb 2023
Cited by: 40 articles | PMID: 35383826 | PMCID: PMC9924904
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy.
Sharpe AN, Oldach MS, Rivas VN, Kaplan JL, Walker AL, Kovacs SL, Hwee DT, Cremin P, Morgan BP, Malik FI, Harris SP, Stern JA
Sci Rep, 13(1):32, 02 Jan 2023
Cited by: 3 articles | PMID: 36593243 | PMCID: PMC9807554
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dendritic spine loss in epileptogenic Type II focal cortical dysplasia: Role of enhanced classical complement pathway activation.
Rossini L, De Santis D, Cecchini E, Cagnoli C, Maderna E, Cartelli D, Morgan BP, Torvell M, Spreafico R, di Giacomo R, Tassi L, de Curtis M, Garbelli R
Brain Pathol, 33(3):e13141, 23 Dec 2022
Cited by: 7 articles | PMID: 36564349 | PMCID: PMC10154370
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Siggins MK, Davies K, Fellows R, Thwaites RS, Baillie JK, Semple MG, Openshaw PJM, Zelek WM, Harris CL, Morgan BP, ISARIC4C Investigators
Immunology, 168(3):473-492, 28 Nov 2022
Cited by: 12 articles | PMID: 36175370 | PMCID: PMC9537932
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.
Sharpe AN, Oldach MS, Kaplan JL, Rivas V, Kovacs SL, Hwee DT, Morgan BP, Malik FI, Harris SP, Stern JA
J Vet Pharmacol Ther, 46(1):52-61, 16 Nov 2022
Cited by: 5 articles | PMID: 36382714 | PMCID: PMC10099566
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 542 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model.

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor.

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [<sup>14</sup>C]aficamten following single oral dose administration to rats.

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility.

Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy.

Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia.

The complement system in neurodegenerative diseases.

Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats.

Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID.

Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model.

Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.

Complement-membrane regulatory proteins are absent from the nodes of Ranvier in the peripheral nervous system.

Complement dysregulation is a predictive and therapeutically amenable feature of long COVID

Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.

Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity.

Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies.

Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis.

Complement receptor 1 is expressed on brain cells and in the human brain.

Membrane-bound complement regulator expression in peripheral nerves

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy.

Dendritic spine loss in epileptogenic Type II focal cortical dysplasia: Role of enhanced classical complement pathway activation.

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.

Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.

Partnerships & funding